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for Disease Prevention and Control, Nanjing, ChinaAbstractMultidrug-resistant tuberculosis (MDR-TB) is prevalent in countries with a high TB burden, like China. As little is known about the emergence
and spread of second-line drug (SLD) -resistant TB, we investigate the emergence and transmission of SLD-resistantMycobacterium tuberculosis in
rural China. In a multi-centre population-based study, we described the bacterial population structure and the transmission characteristics of
SLD-resistant TB using Spoligotyping in combination with genotyping based on 24-locus MIRU-VNTR (mycobacterial interspersed repetitive
unit-variable-number tandem repeat) plus four highly variable loci for the Beijing family, in four rural Chinese regions with diverse
geographic and socio-demographic characteristics. Transmission networks among genotypically clustered patients were constructed using
social network analysis. Of 1332 M. tuberculosis patient isolates recovered, the Beijing family represented 74.8% of all isolates and an
association with MDR and simultaneous resistance between ﬁrst-line drugs and SLDs. The genotyping analysis revealed that 189 isolates
shared MIRU-VNTR patterns in 78 clusters with clustering rate and recent transmission rate of 14.2% and 8.3%, respectively. Fifty-three
SLD-resistant isolates were observed in 31 clusters, 30 of which contained the strains with different drug susceptibility proﬁles and genetic
mutations. In conjunction with molecular data, socio-network analysis indicated a key role of Central Township in the transmission across a
highly interconnected network where SLD resistance accumulation occurred during transmission. SLD-resistant M. tuberculosis has been
spreading in rural China with Beijing family being the dominant strains. Primary transmission of SLD-resistant strains in the population
highlights the importance of routine drug susceptibility testing and effective anti-tuberculosis regimens for drug-resistant TB.
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E-mail: bxu@shmu.edu.cnIntroductionThe global emergence of multidrug-resistant tuberculosis
(MDR-TB; i.e. resistance to at least isoniazid and rifampin) has
brought about formidable challenges to the progress of TBClinical Microbiology and Infection © 2015 European Society of Ccontrol programmes. Second-line drugs (SLDs) are essential for
treating MDR-TB. More recently, the emergence of resistance
to SLDs, and in particular extensively-drug-resistant (XDR) TB,
has further exacerbated therapeutic outcomes and control ef-
forts [1]. Although Mycobacterium tuberculosis isolates resistant
to SLDs have been observed in populations with high burden of
drug resistance, the extent and nature has not been well
elucidated, particularly in MDR-TB hotspot areas [2].
China ranks second among the 22 countries with the highest
TB burden [3] and probably harbours one of the largest res-
ervoirs of individuals latently infected with MDR/XDRClin Microbiol Infect 2015; 21: 1093.e9–1093.e18
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2015.08.023
1093.e10 Clinical Microbiology and Infection, Volume 21 Number 12, December 2015 CMIM. tuberculosis. According to the national baseline survey of
drug-resistant TB conducted in 2010, the frequencies of MDR-
TB among patients with pulmonary TB in China were 8.3% and
1.4% for XDR-TB [4], remaining at a high level. In that same
report, the prevalence of drug-resistant TB including MDR-TB
in the rural region of China was notably higher than the
countrywide average [4]. Improper administration of anti-TB
medications, readily accessible SLDs as well as a relatively
poor case management system for patient follow up during
treatment were cited as reasons for the high prevalence of drug
resistance in rural China [4]. To better understand the un-
derpinnings of drug-resistant TB, there is a need to examine
M. tuberculosis isolates from a deﬁned geographical region.
Although there are molecular epidemiological TB studies from
China, a detailed analysis of M. tuberculosis genetic diversity,
covering both ﬁrst-line drugs (FLDs) and SLDs, resistance in
rural China is lacking.
To better understand the extent of MDR-TB and XDR-TB in
rural China, we conducted a multi-centre population-based
study in four rural counties of China with diverse geographic
and socio-demographic characteristics. We combine molecular
epidemiological and social network analysis to examine the
M. tuberculosis genetic diversity of FLD-resistant and SLD-
resistant TB and elucidate transmission patterns of MDR and
XDR strains in rural China.Materials and methodsStudy design
A population-based study of patients with TB diagnosed at local
TB dispensaries from four rural counties from eastern (Jiangsu
province), middle-western (Sichuan province), southern
(Guangdong Province) and east northern (Shandong Province)
areas in China. All suspected pulmonary TB cases detected in
general hospitals or community health centres were referred to
TB dispensaries for diagnosis and treatment. All patients with
TB notiﬁed in the County TB dispensaries from January 2011 to
December 2013 were enrolled in the study. All protocols in
this study were approved by the ethics committee of the School
of Public Health, Fudan University and written informed con-
sent was obtained from all the patients enrolled.
Drug susceptibility testing
The drug susceptibility testing (DST) for FLDs was determined
with the proportion method [5], using LJ-based medium indi-
vidually with the following drugs: rifampin (40 mg/L), isoniazid
(0.2 mg/L), streptomycin (4.0 mg/L) and ethambutol (2.0 mg/L).
The DST for SLDs was performed according to WHO rec-
ommendations. Critical SLD concentrations for the agarClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectproportion method on 7H10 agar were: oﬂoxacin (2mg/L),
levoﬂoxacin (1mg/L), kanamycin (30 mg/L), capreomycin
(40mg/L), and amikacin (40mg/L). To ensure reproducibility, the
laboratory work underwent external quality assessment by the
Shanghai municipal CDC laboratory.
Deﬁnitions
MDR-TB was deﬁned as an isolate of M. tuberculosis that is
resistant to at least isoniazid and rifampin. XDR was deﬁned as
M. tuberculosis being resistant to at least isoniazid, rifampin, a
ﬂuoroquinolone (FQ; oﬂoxacin or levoﬂoxacin) and one of
three injectable SLDs (capreomycin, kanamycin, or amikacin)
[6]. Pre-XDR was deﬁned as disease caused by the
M. tuberculosis strain resistant to isoniazid and rifampin and
either an FQ or an injectable drug, but not both [7]. Any drug
resistance was deﬁned as an isolate of M. tuberculosis that is
resistant to at least one tested anti-tuberculosis drug. SLD
resistance is deﬁned as an isolates of M. tuberculosis that was
resistant to at least one of the SLDs tested, including those
with additional resistance to the FLDs. New cases were
deﬁned as TB patients who did not have any previous anti-TB
treatment or who received anti-TB treatment for <30 days
before the TB diagnosis. Previously treated cases were TB
patients who reported having been treated for TB for at least
30 days.
DNA isolation and sequencing of loci
DNA from clinical isolates was extracted using the CTAB
method [8]. The following nine resistance-determining loci
were ampliﬁed by PCR: rpoB (rifampin), katG and inhA (isoni-
azid), embB (ethambutol), gyrA (FQ), rrs (kanamycin, capreo-
mycin, and amikacin), eis (kanamycin) and tlyA (capreomycin).
These previously reported drug resistance-determining regions
were ampliﬁed using locus-speciﬁc primers [9]. Sequence data
generated by an ABI 3130xl genetic analyser were reviewed for
conﬁdence levels using an ABI sequence scanner, and chro-
matograms were analysed for the presence or absence of
mutations by comparison with published sequences of H37Rv
using the SeqMan alignment application of the DNASTAR LASER
gene (version 8.0) program.
Spoligotyping
Families of the isolates were determined by spoligotyping using
a commercially available kit (Isogen Bioscience BV, Maarssen,
the Netherlands) [10]. Spoligotyping proﬁles were compared
using the SITVIT_WEB database at Institut Pasteur de
Guadeloupe (http://www.pasteur-guadeloupe.fr:8081/SITVIT_
ONLINE/). Major phylogenetic clades were assigned accord-
ing to the signatures provided in the SpolDB4 database, which
deﬁned 62 discrete genetic lineages/sub-lineages [6].ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1093.e9–1093.e18
FIG. 1. Inclusion of the subjects.
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All the studied isolates were ﬁrst genotyped by the 24-locus
MIRU-VNTR (mycobacterial interspersed repetitive unit-
variable-number tandem repeat) method, as proposed by
Supply et al. [11]. Beijing family strains were further charac-
terized using the four MIRU-VNTR (1982, 3232, 3820 and
4120), previously shown to have high discriminatory power
within Beijing family [12]. The PCR products were detected by
electrophoresis in 2.0% agarose gel using a 100-bp DNA ladder
(Takara Bio Inc., Kusatsu, JAPAN). Size analysis of PCR frag-
ments and assignment of the various MIRU-VNTR alleles were
achieved using QUANTITY ONE (version 4.6.2) software (Bio-Rad
Laboratories, Inc.,Hercules, CA, USA). The 24-locus MIRU-
VNTR digital proﬁles were compared with MIRUVNTRplus
(http://www.miru-vntrplus.org/MIRU/index.faces) for family and
code assignment. MIRU-VNTR clusters were deﬁned on the
basis of identical allelic proﬁles (identical numbers of tandem
repeat units at each MIRU/VNTR locus).
The investigation of epidemiological link
Questionnaire-based interviewing of clustered patients, deﬁned
by MIRU-VNTR genotyping, was performed to collect
comprehensive epidemiological information including de-
mographic characteristics, clinical history, predisposing risk
factors and evidence of contact with patients with active dis-
ease. Information was also obtained on occupational, social and
recreational history, and compliance with TB treatment. Chest
radiographs of all patients were reviewed for the presence of
cavitation.
Transmission network analysis
The transmission network was constructed under the following
criteria: patients were included in a network if they were
infected with clustered M. tuberculosis strain deﬁned by a spe-
ciﬁc MIRU-VNTR genotype. Patients with earlier TB diagnosis
were considered to have transmitted disease to patients who
had a later diagnosis with a shared MIRU-VNTR proﬁle. The
transmission network was drawn with earlier cases on the nock
and later cases on the arrowhead. Furthermore, the individual
transmission networks were compared between central and
peripheral townships in terms of the component size, network
density and centrality [13].
Data analysis
Genotypic data for each isolate at a particular locus were
recorded in a MICROSOFT OFFICE EXCEL 2010 spreadsheet. In-
formation on previous TB treatment was additionally veriﬁed
through medical record review. Data were double-entered in
EPIDATA and checked for errors. Analysis was performed using
SPSS version 19 (IBM SPSS, Chicago, IL, USA). DescriptiveClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infecstatistics were computed for all variables. Means (± standard
deviation) were calculated for continuous variables, whereas
frequencies with percentages were calculated for categorical
variables. To identify factors associated with the molecular
clustering of SLD-resistant M. tuberculosis, univariate and
multivariate logistic regression analyses were performed.ResultsStudy population and drug susceptibility proﬁle
A total of 1417 smear-positive TB patients were registered in
the TB dispensaries during the study period. Twenty-four pa-
tients declined to participate and 28 did not meet the inclusion
criteria. Among the 1365 patients recruited, specimens from 14
were culture-negative, and 19 failed in the DST. These 33 cases
were excluded from the analysis (Fig. 1). As a result, a total of
1332 culture-positive patients with M. tuberculosis infection
were included for analysis. The mean age of patients was 44
(±16.3) years (range 15–91 years), and 927 (69.6%) were male.
Overall, 208 (15.6%) patients had previously been treated for
TB.
Drug susceptibility testing indicated that M. tuberculosis iso-
lates from a total of 623 (46.7%) patients were resistant to at
least one of the anti-tuberculosis agents tested, including four
FLDs (isoniazid, rifampin, streptomycin and ethambutol) and
ﬁve SLDs (oﬂoxacin, levoﬂoxacin, kanamycin, amikacin and
capreomycin). In total 150 isolates (11.3%) were simultaneously
resistant to isoniazid and rifampin and referred to MDR-TB.
Among the 150 MDR-TB isolates, 45 (30.0%) were either
resistant to FQs (31, 20.6%) or the second-line injectable drugs
(14, 9.3%) and were referred to as pre-XDR. In addition, 15
MDR isolates (15/150 or 10.0%) were simultaneously resistanttious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1093.e9–1093.e18
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referred to as XDR (Table 1).
Drug susceptibility proﬁle within different
M. tuberculosis families
Based on Spoligotyping analyses, Beijing family was the pre-
dominant group representing 74.8% (997 of 1332) of all isolates.
Eighty-eight isolates were assigned to four other families: T family
(11.8%), CAS (2.3%), Ural (1.1%), H family (0.9%) and MANU2
(0.8%). One hundred and eight (8.1%) could not be classiﬁed to
previously described lineages and were referred to as ‘Orphans’.
The majority of drug-resistant isolates were within the Beijing
and T families. Of the 997 Beijing family isolates, 136 (13.6%)
were MDR, 273 (27.4%) were resistant to SLD, 42 (4.2%) met
the deﬁnition for pre-XDR, and 15 (1.5%) were XDR.Within the
T family, ten isolates (6.4%) were MDR and ten resistant to SLDs,
whereas MDR isolates were also observed in the CAS and Ural
lineages. No drug resistance was observed in strains labelled as
MANU2 and LAM lineages. (Table 2)
Genetic characterization of drug-resistant TB
Genomic regions known to confer drug resistance to selected
FLDs and SLDs are shown in the Supplementary material
(Table S1). The mutations in katG were identiﬁed in 66.3% of
isoniazid-resistant isolates, all harboured a mutation in codon
315. Mutations related to rifampin resistance occurred mostly
in codon 531 (64.3%), 526 (22.2%) and 516 (7.0%) of the rpoB
gene. Additionally, 73.4% of the FQ resistance was associated
with mutations in gyrA. Of the 123 isolates resistant to kana-
mycin, amikacin and capreomycin, 97 (78.9%) contained mu-
tations within rrs (75; 60.9%) or eis (27; 22.0%).
MIRU-VNTR genotyping and drug-resistant proﬁle
Among 1332 M. tuberculosis strains characterized by VNTR-
MIRU genotyping, 1202 VNTR genotypes were detectedTABLE 1. Baseline information of the subjects
Total No. (%) of isolates resistant to: N
1332
INH RIF F
(n [ 294) (n = 171) (
Area
East 266 49 (18.4) 27 (10.2) 5
South 306 60 (19.6) 37 (12.1) 5
North 361 81 (22.4) 48 (13.3) 4
West 399 104 (26.1) 59 (14.8) 4
Sex
Male 927 201 (21.7) 118 (12.7) 1
Female 405 93 (23.0) 53 (13.1) 7
Age, years 44 ± 16.3 47 ± 16.1 50 ± 17.1 4
Treatment history
New 1124 199 (17.7) 122 (10.9) 1
Previously treated/New 208 95 (45.7) 49 (23.6) 4
Abbreviations: FQs, ﬂuoroquinolones; INH, isoniazid; MDR, multidrug resistance; RIF, rifam
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectincluding 59 VNTR genotypes (clustered) shared by more than
one isolate with the average cluster size of 2.4 (range: 2–4) and
1143 VNTR genotypes observed for only one isolate (unique).
Therefore, the clustering rate and recent transmission rate
were overall 14.2% and 9.8%, respectively, including 10.8% and
5.8% in drug-sensitive strains, 18.0% and 13.0% in drug-resistant
strains.
Among 150 patients with MDR-TB, VNTR genotyping indi-
cated 13 clusters in 27 patients; 123 patients had M. tuberculosis
strains with unique VNTR pattern. The proportion of clustering
and estimation of recent transmission equalled 18.0% and 8.7%,
respectively. Furthermore, within 13 clusters containing MDR-
TB isolates, nine clusters (comprising 27 isolates) contained
MDR-TB and/or additional drug resistance to FQs or one of the
injectable drugs (i.e. pre-XDR-TB). One XDR-TB isolate was in
a cluster containing four isolates that were all resistant to
isoniazid, whereas other XDR-TB isolates were in a cluster
containing ﬁve isolates that were also all resistant to isoniazid.
One cluster with two isolates had identical drug-resistance and
associated mutation proﬁle (Fig. 2). Based on Spoligotyping, 77
isolates in 28 clusters belonged to Beijing genotype.
Risk factors inﬂuencing the clustering proportion of
drug-resistant M. tuberculosis
Clustering proportion among drug-resistant M. tuberculosis
isolates was compared with the 703 drug-susceptible
M. tuberculosis isolates collected simultaneously. Isolates of
M. tuberculosis resistant to isoniazid (24.8% versus 10.8%; p
0.008; OR 2.64; 95% CI 1.816–4.021) and FQs (21.4% versus
10.8%, p 0.043; OR 2.21; 95% CI 1.421–3.487) were more
likely to be clustered compared with drug-susceptible isolates
(Table 3). The association between drug-resistance conferring
genotype and clustering was investigated by comparing the
clustering proportion between drug-resistant genotype and
wild-type isolates. Among isoniazid-resistant strains, the alleleso. (%) of isolates resistant to: No. (%) of isolates with:
Qs Injective MDR Pre-XDR XDR
n = 192) (n = 123) (n = 150) (n = 45) (n = 15)
1 (19.1) 34 (12.8) 21 (7.9) 8 (3.0) 2 (0.8)
8 (18.9) 36 (11.8) 28 (9.2) 9 (2.9) 3 (1.0)
0 (11.1) 32 (8.9) 44 (12.2) 11 (3.0) 4 (1.1)
3 (10.8) 21 (5.3) 57 (14.3) 17 (4.3) 6 (1.5)
22 (13.2) 79 (8.5) 102 (11.0) 28 (3.0) 10 (1.1)
0 (17.3) 44 (10.9) 48 (11.8) 17 (4.2) 5 (1.2)
5 ± 19.5 50 ± 21.3 53 ± 15.1 55 ± 17.1 61 ± 15.3
51 (13.4) 98 (8.7) 101 (9.0) 35 (3.1) 8 (0.7)
1 (19.7) 25 (12.0) 49 (23.6) 10 (4.8) 7 (3.4)
pin; XDR, extensively drug resistance.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1093.e9–1093.e18
TABLE 2. Drug susceptibility patterns within different M. tuberculosis strain lineages
Beijing T CAS H MANU2 LAM Ural Orphans
n [ 997 n = 157 n [ 30 n [ 12 n [ 10 n = 3 n = 15 n [ 108
First-line drug-resistant pattern
INH 266 (26.7) 15 (9.5) 3 (10.0) 1 (8.3) 0 (0) 0 (0) 2 (13.3) 7 (6.5)
RIF 157 (15.7) 11 (7.0) 1 (3.3) 1 (8.3) 0 (0) 0 (0) 1 (6.7) 0 (0)
Second line drug-resistant pattern 0 (0)
FQs 178 (17.9) 11 (7.0) 2 (6.7) 1 (8.3) 0 (0) 0 (0) 0 (0) 0 (0)
KAN, CAP, AMK 112 (11.2) 6 (3.8) 3 (10.0) 2 (16.7) 0 (0) 0 (0) 0 (0) 0 (0)
First- and second-drug cross-resistant pattern 0 (0)
MDR 136 (13.6) 10 (6.4) 2 (6.7) 1 (8.3) 0 (0) 0 (0) 1 (6.7) 0 (0)
Pre-XDR-TB 42 (4.2) 3 (1.9) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
XDR-TB 15 (1.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Abbreviations: AMK, amikacin; CAP, capreomycin; INH, isoniazid; KAN, kanamycin; MDR, multidrug resistance; RIF, rifampin; TB, tuberculosis; XDR, extensively drug resistance.
CMI Hu et al. Second-line drug resistant TB in China 1093.e13with the mutation in katG (30.8% versus 11.8%; p 0.001; OR
3.39; 95% CI 2.312–4.897) were associated with clustering. No
other alleles conferring resistance to FLDs or SLDs were
associated with clustering.
In the multivariate analysis (Table 4), Beijing family strain had
a signiﬁcantly higher proportion of clustering than those from
other strain families among SLD-resistant M. tuberculosis and
accounted for all the clustered FLD- and SLD-resistant and pre-
XDR isolates. Previous treatment with FLDs was independently
associated with clustering among drug-resistant M. tuberculosis
isolates (30.0% versus 15.1%; OR 2.41; 95% CI 1.349–4.341)
and SLD resistance (41.9% versus 18.3%; OR 3.10; 95% CI
1.034–10.85). A history of TB contact signiﬁcantly increased
the risk of clustering among any drug-resistant M. tuberculosis
isolates (38.3% versus 20.7%; OR 4.04; 95% CI 2.235–7.345)
and SLD-resistant M. tuberculosis isolates (45.0% versus 17.9%;
OR 3.94; 95% CI 1.014–9.650). Furthermore, among the SLD
resistance, isolates from smear-positive patients were more
likely to be clustered than smear-negative individuals (31.7%
versus 11.0%; OR 3.58; 95% CI 1.086–13.66).
Epidemiological link and social network analysis
Epidemiological links within drug-resistant clusters were
further analysed by contact investigation. Transmission net-
works were constructed between MIRU-VNTR-deﬁned clus-
ters containing drug-resistant TB cases (Fig. 3). Of the 31
clusters, 24 were considered inter-regional spread from the
Centre Township to the Peripheral Township involving 20
MDR strains, 32 non-MDR isolates resistant to SLDs and 11
pre-XDR/XDR-TB strains. The Centre Township of the studied
counties contained 30 clusters, involving 20 MDR-TB isolates,
19 isolates resistant to SLDs and nine pre-XDR and two XDR-
TB isolates. Examining putative epidemiological links, 14 of 84
(16.7%) molecularly clustered isolates were recovered from
family members (household contact), friends or colleagues
(social contact). No epidemiological links or geographic cor-
relations were established for 15 clustered drug-resistantClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infecisolates. For network parameters, central townships were the
true centre of the TB transmission network, with size of this
largest node up to ﬁve and highest ties up to 20. Additionally,
the central township also had the higher average geodesic dis-
tance and betweenness compared with the peripheral township
(see Supplementary material, Table S2).DiscussionChina is a country with considerable TB incidence and preva-
lence. Of growing concern is the high burden of MDR-TB cases
in rural areas. This study reports on the extent and genetic
diversity of the circulating bacillary population that is resistant
to FLDs and SLDs in eastern rural China, an area with a pop-
ulation of over 656 million (The Sixth National Population
Census of China, 2010). We report that SLD resistance is
considerable among both MDR (40%) and non-MDR (14.8%)
TB populations.
Consistent with previous reports, genotyping results indicate
that the Beijing family of strains are over-represented in this
population [14–16]. Although other strain families were rep-
resented (i.e. T1, H, MANU2 and LAM), MDR-TB and pre-
XDR-TB were only found within Beijing, CAS, H, Ural and
T1 families. The distribution of non-MDR and MDR-TB clinical
isolates within the lineages varied. Whereas Beijing strains
represented over 90.7% of MDR isolates, this percentage
increased to around 95% among pre-XDR-TB and XDR clinical
isolates. Monitoring Beijing strains and their drug susceptibilities
may inform MDR-TB and XDR-TB control strategies.
To study the emergence of SLD resistance, we examined the
drug susceptibility proﬁles and genetic correlates of resistance
within MIRU-VNTR-deﬁned clusters. Among 31 clusters with
SLD resistance, 30 contained isolates with different drug sus-
ceptibility proﬁles whereas only one cluster had isolates with
the same drug-resistant pattern. The high proportion of isolates
with different genotypic patterns and drug-resistance proﬁlestious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1093.e9–1093.e18
FIG. 2. The drug-resistance proﬁle and genetic mutation of the clustered Mycobacterium tuberculosis strain.
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TABLE 4. Factors associated with the clustering of second-line drug-resistant Mycobacterium tuberculosis strains
Total Clustered (%) OR (95% CI) Adjusted OR(95% CI)
Total drug resistance
City/rural 122/300 13.4/20.4 0.59 (0.304–1.099) 0.57 (0.291–1.154)
Female/Male 285/137 19.8/15.6 1.35 (0.761–2.466) 1.37 (0.754–2.507)
Age(years) 47 ± 19.9 vs 47 ± 20.5 1.02 (0.981–1.029) 1.03 (0.982–1.107)
Previously treated/New 94/328 30.0/15.1 2.41 (1.352–4.252)a 2.41 (1.349–4.341)a
BMI(values) 20 ± 12.3 vs 19 ± 4.4 0.98 (0.936–2.875) 0.99 (0.927–1.084)
Cavity/No 77/345 20.9/14.1 1.61 (0.911–2.936) 1.65 (0.832–2.999)
Smear-positive/negative 261/161 18.3/12.3 1.03 (0.599–1.776) 1.03 (0.537–1.795)
TB contacts/no 80/342 38.3/20.7 4.07 (2.257–7.263) 4.04 (2.235–7.345)a
Beijing genotype/no 328/94 18.7/7.4 1.11 (0.593–2.190) 1.09 (0.587–2.223)
Second-line drug resistance
City/rural 53/182 19.0/23.6 0.75 (0.310–1.685) 0.76 (0.165–2.803)
Female/Male 152/83 25.0/18.1 1.51 (0.745–3.180) 1.2 (0.378–3.809)*
Age(years) 49 ± 18.2 vs 49 ± 21.2 1.00 (0.983–1.025) 1.0 (0.977–1.030)
Previously treated/New 43/192 41.9/18.3 3.23 (1.480–6.916)a 3.10 (1.034–10.85)*
BMI(values) 18 ± 4.9 vs 19 ± 14.6 0.98 (0.953–1.034) 0.99 (0.930–1.054)
Cavity/No 91/144 27.8/19.3 1.64 (0.838–3.201) 1.61 (0.531–4.796)
Smear positive/negative 126/109 31.7/11.0 3.33 (1.604–7.225)a 3.58 (1.086–13.66)*
TB contacts/no 40/195 45/17.9 3.74 (1.688–8.156)a 3.94 (1.014–9.650)*
Beijing genotype/no 171/64 28.1/7.8 4.60 (1.796–15.52)a 4.46 (1.050–12.17)*
First- and second-line drugs cross-resistance
City/rural 30/67 30.0/31.3 0.94 (0.322–2.599) 0.91 (0.205–3.159)
Female/Male 24/73 25.0/32.9 0.68 (0.196–2.101) 0.62 (0.147–2.848)
Age(years) 49 ± 5.5 vs 51 ± 5.0 0.99 (0.955–1.039) 0.97 (0.913–1.042)
Retreatment/New 27/70 33.3/30.0 1.17 (0.394–3.287) 1.17 (0.342–3.939)
BMI(values) 18 ± 5.0 vs 21 ± 5.5 1.09 (0.934–1.276) 1.09 (0.931–1.278)
Cavity/No 36/61 33.3/18 1.19 (0.443–3.150) 1.12 (0.374–3.963)
Smear positive/negative 76/21 36.8/9.5 5.54 (1.173–11.89)a 5.58 (1.134–12.93)a
TB contacts/no 18/79 66.7/22.8 6.78 (1.972–24.77)a 6.57 (1.806–28.50)a
Beijing genotype/no 84/13 32.1/23.1 1.58 (0.364–9.604) 1.54 (0.336–10.95)
Pre-XDR/XDR-TB
City/rural 17/43 11.7/23.3 0.44 (0.042–2.491) 0.43 (0.027–2.943)
Female/Male 22/38 18.1/21.0 0.78 (0.154–3.377) 0.53 (0.134–4.436)
Age(years) 50 ± 8.3 vs 51 ± 8.8 0.97 (0.919–1.031)
Retreatment/New 16/43 31.3/15.6 1.90 (0.343–8.958) 1.11 (0.015–12.94)
BMI(values) 17 ± 7.8 vs 19 ± 7.3 1.06 (0.864–1.235) 1.05 (0.851–1.293)
Cavity/No 25/35 28.0/14.3 2.33 (0.536–10.69) 2.36 (0.486–11.34)
Smear positive/negative 53/7 22.2/0 –
TB contacts/no 13/47 61.5/8.5 3.57 (0.690–17.03 3.50 (0.558–18.51)
Beijing genotype/no 54/6 22.2/0 – –
Abbreviations: WT, wild type; MDR-TB, multidrug-resistant tuberculosis; XDR, extensively drug resistant.
*p <0.05.
aOR and 95% CI were adjusted by age, sex and county of subjects in binary logistic regression model.
TABLE 3. Clustering proportion in Mycobacterium tuberculosis isolates by drug-resistant patterns and genetic mutations
No. of isolates Unadjusted Adjusted
Total Clustered (%) OR 95% CI ORa 95% CIa
Isolates resistant to:
Drug susceptible 703 76 (10.8) 1
INH 294 73 (24.8) 2.73 1.877–3.949* 2.64 1.816–4.021*
RIF 171 27 (15.8) 1.55 0.923–2.530 1.57 0.902–2.631
STR 255 16 (6.3) 0.55 0.295–0.980 0.56 0.291–0.991
EMB 136 19 (14.0) 1.34 0.736–2.340 1.39 0.721–2.386
FQs 192 41 (21.4) 2.24 1.432–3.465* 2.21 1.421–3.487*
CAP, AMK, KAN 123 19 (15.4) 1.51 0.825–2.664 1.52 0.745–2.591
MDR-TB 150 27 (18.0) 1.81 1.075–2.978* 1.73 1.061–2.993*
Pre-XDR/XDR-TB 60 12 (20.0) 2.06 1.022–4.156* 2.04 1.013–5.123*
Drug-resistant isolates with mutation in:
WT 910 107 (11.8)
katG 195 60 (30.8) 3.37 2.322–4.862* 3.39 2.312–4.897*
rpoB 163 27 (16.6) 1.49 0.903–2.392 1.53 0.889–2.413
rpsL 160 13 (8.1) 0.66 0.333–1.224 0.45 0.312–1.235
embB 81 12 (14.8) 1.31 0.622–2.529 1.23 0.612–2.632
gyrA 141 24 (17.0) 1.54 0.906–2.533 1.49 0.893–2.564
rrs 75 10 (13.3) 1.15 0.513–2.350 1.13 0.498–2.381
eis 27 3 (11.1) 0.94 0.178–3.169 0.89 0.173–3.253
Abbreviations: AMK, amikacin; CAP, capreomycin; EMB, ethambutol; FQs, ﬂuoroquinolones; INH, isoniazid; KAN, kanamycin; MDR, multidrug resistance; RIF, rifampin; STR,
streptomycin; TB, tuberculosis; WT, wild-type; XDR, extensively drug resistance.
*p <0.05.
aOR and 95% CI were adjusted by age, sex and county of subjects in binary logistic regression model.
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FIG. 3. The network analysis of the clusters containg the drug-resistant Mycobacterium tuberculosis isolates Each symbol refers to individual clustered
patients and each number refers to the cluster number. Abbreviations: DS, drug sensitive; MDR-TB, multidrug-resistant tuberculosis; XDR, extensively
drug resistant.
1093.e16 Clinical Microbiology and Infection, Volume 21 Number 12, December 2015 CMIsuggests that de novo or acquired resistance rather than primary
transmission of drug resistance is driving SLD-resistant TB in
rural China. Importantly, 22.6% of the analysed strains in these
clusters were pre-XDR-TB. These data indicate that appro-
priate means to prevent emergence of SLD resistance among
MDR-TB patients are not in place.
When comparing the drug resistance-related genotypes
within clusters containing SLD-resistant isolates, we found that
mutations occurring in katG and gyrA genes were cluster
associated. The mutation katG 315Thr occurred exclusively in
17 clusters and gyrA D94G were exclusive to two clusters.
Furthermore, 45 of 47 isoniazid-resistant isolates in 16 clusters
had the katG 315Thr mutation, which was strongly associated
with the mutations in rpoB and gyrA mutation, respectively.
Additionally, eight isolates had the gyrA D94G mutation that
was associated with the rrs A1401G mutation. These data
illustrate possible instances of primary transmission of drug-
resistant strains, although no patient data were available to
establish epidemiological linkage. Given the high number of
MDR-TB strains with FQ resistance and the high clusteringClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectproportion of FQ-resistant strains with gyrA mutation, rapid
molecular diagnostics to evaluate gyrA before treatment with
SLD may be warranted.
In the present study, a number of patient factors were
associated with molecular clustering. We found that sputum
smear positivity and having a recent contact with a TB patient
were associated with clustering, consistent with previous re-
ports [17–19]. Higher bacillary loads among clustered cases
may indicate intrinsic strain-speciﬁc properties; but it is more
likely to be related to delayed health-seeking behaviour. Con-
tact with a patient who had TB diagnosed was an important
indicator for clustering with drug-resistant strains. Additionally,
previously treated subjects were more likely to be clustered,
especially when they are infected with drug-resistant or SLD-
resistant M. tuberculosis. This might point to the fact that pre-
viously treated TB patients may be at increased risk of re-
infection rather than reactivation [20]. Paramount is the
improvement of case management of drug-resistant patients to
ensure favourable treatment outcomes and prevent primary
transmission in the community. If effective measures are notious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1093.e9–1093.e18
CMI Hu et al. Second-line drug resistant TB in China 1093.e17put in place to avoid the transmission of these strains, the
inherently high treatment costs for MDR-TB and XDR-TB will
place undue burden for national/local tuberculosis control
programmes [21,22].
In this study, we examined the role of recent transmission
among patients harbouring SLD-resistant and/or XDR-TB in
rural China. We found that the majority of SLD resistant pa-
tients in clusters live in a Central Township and/or experienced
contact with a TB patient. Furthermore, social network analysis
indicated that, rather than a point source outbreak from a single
patient; there was a high degree of interconnectedness that
allowed multiple transmission events of drug-resistant
M. tuberculosis strains over time. Drug-resistant TB trans-
mission is probably occurring in the Central Township, where
the local TB dispensary is located. The congregation of TB
patients may allow nosocomial transmission of drug-resistant
organisms. In addition, the long delay in diagnosing MDR/
XDR-TB probably contributes to community transmission.
Although infectiousness of TB patients can be highly variable,
studies have consistently shown that patients receiving inade-
quate treatment regimens, including those for drug-resistant
TB, account for the majority of transmission events [19].
Around 80% of MDR and pre-XDR-TB strains are not
clustered, suggesting that MDR, pre-XDR and XDR strains are
being built (acquired) and not transmitted in rural China.
However, clustering of drug-resistant M. tuberculosis can be
observed in 10% of individuals with no previous history of TB,
as well as in 15% of individuals with a history of previous TB
treatment. A recent meta-analysis also showed that primary
drug resistance was associated with poor treatment outcomes
if treatment regimens were not based on drug susceptibility test
results [23,24]. In communities with a high rate of primary drug
resistance, approaches that assign treatment regimens based
solely on the patient’s history of previous treatment may
amplify drug resistance. Patients with MDR and XDR TB in
China are often poor and cannot afford the SLDs, making it
difﬁcult to achieve treatment success. Patients with MDR and
XDR TB without adequate treatment regimens will continue to
be sources of infection in their communities. Therefore, con-
trol strategies must include efforts to improve cure rates for
susceptible and MDR-TB cases, including infection control
programmes to prevent transmission of drug-resistant
M. tuberculosis strains. The success of infection control pro-
grammes hinges on their ability to promptly identify and sepa-
rate XDR-TB patients from other patients [25]. Hence, in
addition to well-recognized administrative, environmental and
personal protection measures, implementation of rapid diag-
nostic testing for TB drug resistance [26] and redesign of
healthcare facilities to minimize spaces where people congre-
gate (e.g. wards and outpatient waiting areas) are criticalClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infecelements of infection control programmes. Although ﬁnancial
and human resources are limited in developing countries,
implementing such strategies has proven cost-effective when
compared with the large public health and social costs of an
escalating epidemic.
This study is subject to the usual limitations in survey design
and data collection. Although restricted to the local TB dis-
pensaries in rural China, these four dispensaries were
responsible for diagnosing and treating approximately 85% of
TB cases in study regions. Previous TB treatment was veriﬁed
through medical record review when available, but it is possible
for patients not to report TB history so as to either receive free
treatment or avoid receiving daily streptomycin injections and
longer treatment course. Although such a bias could lower our
estimate of new MDR-TB and pre-XDR/XDR-TB prevalence,
most of the cases were unclustered in the present study, which
could suggest that these biases might not play a role and a
substantial number of drug-resistant TB cases would be diag-
nosed if all TB cases were to be tested.
In conclusion, we report substantial SLD resistance among
both MDR and non-MDR groups. The detailed molecular
analysis coupled with treatment history indicates that SLD
resistance is acquired (de novo) most probably due to inap-
propriate use of SLD rather than primary transmission. This
study highlights the utmost importance of strict regulation in
the prescription of SLDs and careful patient management. In
addition, our study underscores the needs for drug suscepti-
bility testing and rapid diagnostics to effectively control drug-
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